leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sci PLC - Issue of Equity on Exercise of Warrants

RNS Number : 5252C
Tiziana Life Sciences PLC
20 October 2020
 

Tiziana Life Sciences Plc

("Tiziana" or the "Company")

Issue of Equity on Exercise of Warrants

London, New York, 20 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 35,714 ordinary shares of 3 pence each ("New Ordinary Shares") credited as fully paid at a price of 70 pence per share in respect of the exercise of 35,714 warrants held by Optiva Securities Limited.

Application has been made for the 35,714 New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on or around 23 October 2020. The New Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

Total Voting Rights

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following the issue of the New Ordinary Shares to be issued in connection with the exercise of the warrants, the total number of Ordinary Shares in issue will be 191,476,787. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 191,476,787 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.

For further enquiries:

 

United Kingdom:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder                                            +44 (0)20 7495 2379

 

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner                                                                      +44 (0)20 7213 0880

 

Optiva Securities Limited (Broker)

Robert Emmet                                                                                      +44 (0)20 3981 4173

 

United States:

Investors

Dave Gentry

RedChip Companies Inc.

001 407 - 491 - 4498

[email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEASENFFPEFFA

Quick facts: Tiziana Life Sciences PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE calms as optimism vaccine news is challenged by rise in...

FTSE 100 had a lukewarm start on Wednesday as positive vaccine news can’t change the current rise in infections and global lockdowns. London’s leading index advanced 11 points to 6,308 in early dealing. JD Wetherspoon PLC (LON:JDW) has posted a 28% slump in sales over the past four months...

2 weeks, 6 days ago

4 min read